Board of Directors
Sten Scheibye, Chairman
Sten Scheibye is chairman of the Board of Directors of Novo Nordisk A/S. From 1995 to 2008 he was president and CEO of Coloplast A/S, Denmark. Before joining Coloplast in 1993, Mr Scheibye served as senior vice president, sales & marketing in Leo Pharma A/S, Denmark. He joined Leo Pharma in 1981.
Mr Scheibye is chairman of the Board of Directors of the Trade Council of Denmark and the Danish Industry Foundation and a member of the boards of the Novo Nordisk Foundation, Rambøll Gruppen A/S, DADES A/S, RM Rich. Müller A/S, the Rich. Müller Foundation, the Aase and Ejnar Danielsen Foundation and the Knud Højgaards Foundation, all in Denmark.
Furthermore, he is chairman of the Denmark-America Foundation and vice chairman of the Danish Fulbright Commission.
Mr Scheibye has an MSc in Chemistry and Physics from 1978 and a PhD in Organic Chemistry from 1981, both from the University of Aarhus, Denmark, and a BComm from the Copenhagen Business School, Denmark, from 1983.
Mr Scheibye was first elected to the Board of Novo Nordisk A/S in 2003 and has been re-elected several times, most recently in 2012. He became vice chairman in 2004 and chairman in 2006. His term as a board member expires in March 2013.
In April 2012, the Board of Directors of Novo Nordisk A/S assessed that Mr Scheibye is not regarded as an independent board member as defined in Section 5.4.1 of the Recommendations on Corporate Governance designated by NASDAQ OMX Copenhagen (2011) due to his membership of the Board of the Novo Nordisk Foundation. In February 2012, the Board of Directors assessed that the special competences possessed by Mr Scheibye that are important for the performance of his duties are his knowledge of the healthcare industry, particularly in relation to patients requiring chronic care, and managerial skills relating to international organisations.
Mr Scheibye is a male Danish national, born October 1951.